Eplivanserin

Drug Profile

Eplivanserin

Alternative Names: Ciltyri; Sliwens; SR 46349; SR 46349B; SR 46615A

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Fluorobenzenes; Phenols; Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Anxiety disorders; Apnoea; Insomnia; Major depressive disorder; Myocardial infarction

Most Recent Events

  • 22 Dec 2009 Discontinued - Preregistration for Insomnia in European Union (PO)
  • 22 Dec 2009 Discontinued - Preregistration for Insomnia in USA (PO)
  • 16 Sep 2009 Sanofi-Aventis receives complete response letter from the US FDA for eplivanserin in Insomnia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top